Eli Lilly and Company has reported positive results from several Phase 3 clinical trials to assess its new once-weekly basal insulin, efsitora alfa. The trials, which are part of the QWINT program (QWINT-1, QWINT-3, and QWINT-4), explored the safety and efficacy of efsitora alfa in adult patients with type 2 diabetes.
The results consistently demonstrated that efsitora alfa achieved a non-inferior reduction in A1C levels compared to daily basal insulin regimens.In the QWINT-1 study, efsitora alfa led to a significant A1C reduction of 1.31%, closely matching the 1.27% reduction observed with insulin glargine.
The QWINT-3 trial again supported these results, with efsitora alfa resulting in an A1C reduction of 0.86%, which was similar to the 0.75% reduction with insulin degludec.
Last, in the QWINT-4 trial, efsitora alfa resulted in a reduction of 1.07% for A1C, equal to the reduction that occurred with insulin glargine.
These strong results suggest that efsitora alfa may provide an easy and effective option for type 2 diabetes patients, with the potential for increased treatment adherence as a result of its once-weekly dosing regimen.
Eli Lilly has said that it will submit efsitora alfa for the treatment of adults with type 2 diabetes to worldwide regulatory authorities by the end of this year. This would potentially introduce a major new choice in diabetes treatment, providing a less frequent injection regimen for patients who need basal insulin.
Last Modified:
Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.
